ABBV250110C182500
- 0.07
- -0.27-79.41%
AbbVie Newsroom
Express News | Light Horse: Financing Led by Versant Ventures and Included Mubadala Capital, Bristol-Myers, Taiho Ventures, and Abbvie
Express News | Light Horse Therapeutics Debuts With $62 Mln Series a Financing
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
AbbVie's Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Congress Trade: Representative Virginia Foxx Just Disclosed New Stock Trades
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Assessing AbbVie: Insights From 17 Financial Analysts
8 Health Care Stocks Whale Activity In Today's Session
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Resilience Partners With Parvus Therapeutics for Development and Manufacturing of PVT401, a Novel Autoimmune Drug Candidate for IBD
AbbVie Price Target Cut to $211.00/Share From $215.00 by Truist Securities
AbbVie Analyst Ratings
Truist Financial Maintains AbbVie(ABBV.US) With Buy Rating, Announces Target Price $211
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
AbbVie (ABBV) Stock Moves -0.32%: What You Should Know
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock